Floatz logo

PEGFILGRASTIM

Hodgkin's Disease

Michael Spinner, MDprotein_peptidePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hodgkin's Disease cohort.

Asset / SponsorPhaseRating
Benadryl
City of Hope Medical Center
Phase 2BB
PENTOSTATIN
St. Jude Children's Research Hospital
Phase 3BB
Basiliximab
City of Hope Medical Center
Phase 2BB
Umbilical Cord Blood Cell Infusion
Mesoblast, Ltd.
Phase 3B
Stemex®
Gamida Cell -Teva Joint Venture Ltd.
Phase 2/3B

View all 30 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →